Awaiting Data, BioMarin Pads Coffers with $249M Offering

As it prepares for the readouts from a handful of clinical trials in the second half of the year, rare disease developer BioMarin Pharmaceutical Inc. turned to the markets to seek $248.8 million from an underwritten public offering of 6.5 million shares of common stock.